JP2005532051A - ヒト化抗リンホトキシンβレセプター抗体 - Google Patents

ヒト化抗リンホトキシンβレセプター抗体 Download PDF

Info

Publication number
JP2005532051A
JP2005532051A JP2004518186A JP2004518186A JP2005532051A JP 2005532051 A JP2005532051 A JP 2005532051A JP 2004518186 A JP2004518186 A JP 2004518186A JP 2004518186 A JP2004518186 A JP 2004518186A JP 2005532051 A JP2005532051 A JP 2005532051A
Authority
JP
Japan
Prior art keywords
antibody
seq
light chain
heavy chain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004518186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005532051A5 (https=
Inventor
エレン ガーバー，
ケネス シモン，
ジョゼ サルダンハ，
Original Assignee
バイオジェン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオジェン， インコーポレイテッド filed Critical バイオジェン， インコーポレイテッド
Publication of JP2005532051A publication Critical patent/JP2005532051A/ja
Publication of JP2005532051A5 publication Critical patent/JP2005532051A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2004518186A 2002-07-01 2003-07-01 ヒト化抗リンホトキシンβレセプター抗体 Pending JP2005532051A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39299302P 2002-07-01 2002-07-01
US41737202P 2002-10-09 2002-10-09
PCT/US2003/020762 WO2004002431A2 (en) 2002-07-01 2003-07-01 Humanized anti-lymphotoyin beta receptor antibodies

Publications (2)

Publication Number Publication Date
JP2005532051A true JP2005532051A (ja) 2005-10-27
JP2005532051A5 JP2005532051A5 (https=) 2006-08-17

Family

ID=30003289

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004518186A Pending JP2005532051A (ja) 2002-07-01 2003-07-01 ヒト化抗リンホトキシンβレセプター抗体

Country Status (10)

Country Link
US (1) US7429645B2 (https=)
EP (1) EP1539793A4 (https=)
JP (1) JP2005532051A (https=)
CN (1) CN1678625A (https=)
AR (1) AR040367A1 (https=)
AU (1) AU2003248782A1 (https=)
CA (1) CA2491480A1 (https=)
NZ (1) NZ537965A (https=)
TW (1) TW200416044A (https=)
WO (1) WO2004002431A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023506750A (ja) * 2019-12-11 2023-02-20 シラグ・ゲーエムベーハー・インターナショナル Ｌｔｂｒ及びｅｄｂ結合ドメインを含む多重特異性結合分子並びにその使用
JP2025500949A (ja) * 2021-12-20 2025-01-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト アゴニストｌｔｂｒ抗体及びそれらを含む二重特異性抗体

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2344049C (en) * 1998-10-09 2009-12-15 Biogen, Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
MXPA03003144A (es) * 2000-10-13 2004-12-06 Biogen Inc Anticuerpos humanizados anti-lt-??-r.
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
JP2006513225A (ja) * 2002-12-20 2006-04-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 化学療法剤と組み合わせたリンホトキシンβ受容体因子
CA2529945A1 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
JP2005241389A (ja) * 2004-02-25 2005-09-08 Ochiyanomizu Jiyoshi Univ 蛍光標識糖鎖の特異的固定化試薬および固定化方法
AU2005227322A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
KR20090078349A (ko) 2006-10-12 2009-07-17 제넨테크, 인크. 림포톡신-알파에 대한 항체
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
JP2010506955A (ja) * 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
US20090074780A1 (en) 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
JP2012514458A (ja) * 2008-12-31 2012-06-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗リンホトキシン抗体
JP2013529076A (ja) 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｆｇｆｒ２抗体
TWI897855B (zh) * 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
WO2025012620A1 (en) 2023-07-07 2025-01-16 Mestag Therapeutics Ltd Binding constructs
EP4527851A1 (en) 2023-09-22 2025-03-26 Bayer Aktiengesellschaft Bispecific antibodies binding ltbr and lrrc15
WO2025172587A1 (en) 2024-02-16 2025-08-21 Mestag Therapeutics Ltd Binding constructs
WO2025172588A1 (en) 2024-02-16 2025-08-21 Mestag Therapeutics Ltd Bispecific constructs directed against fap and ltbr
WO2025221728A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992000329A1 (en) 1990-06-27 1992-01-09 Biogen, Inc. Surface complexed lymphotoxin
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69334224D1 (de) 1992-12-04 2008-07-17 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
CN1900116A (zh) * 1995-01-26 2007-01-24 拜奥根Idec马萨诸塞公司 抗－LT－β－R抗体、含有该抗体的药用组合物及其制药应用
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
ES2211035T3 (es) 1998-01-30 2004-07-01 Biogen, Inc. Tratamiento de linfomas foliculares usando inhibidores de la ruta de la linfotoxina (lt).
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
MXPA03003144A (es) * 2000-10-13 2004-12-06 Biogen Inc Anticuerpos humanizados anti-lt-??-r.
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
JP2006513225A (ja) * 2002-12-20 2006-04-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 化学療法剤と組み合わせたリンホトキシンβ受容体因子
AU2005227322A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023506750A (ja) * 2019-12-11 2023-02-20 シラグ・ゲーエムベーハー・インターナショナル Ｌｔｂｒ及びｅｄｂ結合ドメインを含む多重特異性結合分子並びにその使用
JP7837867B2 (ja) 2019-12-11 2026-03-31 シラグ・ゲーエムベーハー・インターナショナル Ｌｔｂｒ及びｅｄｂ結合ドメインを含む多重特異性結合分子並びにその使用
JP2025500949A (ja) * 2021-12-20 2025-01-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト アゴニストｌｔｂｒ抗体及びそれらを含む二重特異性抗体

Also Published As

Publication number Publication date
CA2491480A1 (en) 2004-01-08
EP1539793A2 (en) 2005-06-15
CN1678625A (zh) 2005-10-05
EP1539793A4 (en) 2006-02-01
US20060222644A1 (en) 2006-10-05
NZ537965A (en) 2008-04-30
AU2003248782A1 (en) 2004-01-19
US7429645B2 (en) 2008-09-30
WO2004002431A2 (en) 2004-01-08
WO2004002431A3 (en) 2004-08-26
AR040367A1 (es) 2005-03-30
TW200416044A (en) 2004-09-01

Similar Documents

Publication Publication Date Title
JP2005532051A (ja) ヒト化抗リンホトキシンβレセプター抗体
EP1504035B1 (en) Antibodies specific for human cd22 and their therapeutic and diagnostic uses
AU2008232409C1 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
EP2021370B1 (en) Trail receptor-binding agents and uses of the same
EP4112647A1 (en) Anti-cd47/anti-pd-l1 antibody and applications thereof
CA2425809A1 (en) Humanized anti-lt-.beta.-r antibodies
US9290571B2 (en) Antibodies to EphA3
CA2619298A1 (en) Modified antigen binding molecules with altered cell signaling activity
JP7773239B2 (ja) Ｐｄ－ｌ１及びｃｄ４７に対する二重特異性単一ドメイン抗体及びその用途
KR20230070238A (ko) 4-1bb를 표적으로 하는 단일 도메인 항체, 이의 융합 단백질, 이의 약제학적 조성물 및 용도
US20240190990A1 (en) Anti-cea antibodies and methods of use
US20240190989A1 (en) Anti-cea and anti-cd137 multispecific antibodies and methods of use
CA2595398A1 (en) Treatment of b-cell malignancies
AU2002346127B2 (en) Humanized antibody against fibroblast growth factor-8 and fragment of the antibody
AU2013203712A1 (en) Binding Proteins, Including Antibodies, Antibody Derivatives And Antibody Fragments, That Specifically Bind CD154 And Uses Thereof
HK1071762B (en) Antibodies specific for human cd22 and their therapeutic and diagnostic uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090501